Our MP1000 Platform

MetrioPharm AG is developing a new class of drugs to enable a full lifespan free of chronic and degenerative diseases.

Compounds from the MP1000 platform are orally available small molecules with a potent anti-inflammatory activity targeting the reduction of oxidative stress in immune cells.

MetrioPharm AGs lead compound MP1032 has demonstrated pronounced anti-inflammatory and disease-modifying activity in a number of disease models.

Our Lead Drug MP1032

Targeted Mechanism of Action   Metriopharm AG - checked MP1032 acts at the very top of the inflammatory cascade and downregulates multiple inflammatory pathways
Superior Safety Metriopharm AG - checked 99 patients were dosed up to 12 weeks with up to 600 mg/day with excellent safety results
Clinical Efficacy  Metriopharm AG - checked Phase II study with 151 patients confirmed superior risk/benefit profile
Multiple Indications  Metriopharm AG - checked MP1032 shows proof-of-principle in animal models of other autoimmune/inflammatory indications such as rheumatoid arthritis (RA), relapsing-remitting multiple sclerosis (MS), and inflammatory bowel diseases (IBD)
Convenient Oral Drug  Metriopharm AG - checked Suitable for development as an oral monotherapy and in combination with other anti-inflammatory therapies